drugset / Trial / NCT04807816
Targeting ATR in Soft-tissue Sarcomas
Phase 2
Completed
58 enrolled
Institut Bergonié
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of berzosertib in association with gemcitabine
Timeline
- Start
- 2022-02-09
- Primary completion
- 2024-09-29
- Completion
- 2026-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Berzosertib | Small molecule | 210 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |